<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DORYX- doxycycline hyclateÂ capsule, delayed release pelletsÂ </strong><br>Warner Chilcott (US), Inc.<br></p></div>
<h1>DORYX<span class="Sup">Â® </span>Â (doxycycline hyclate) Delayed-Release Capsules, 75 mg and 100 mg</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D6F89F3B-CF46-485E-B12F-1EC7C0BF9A2D"></a><a name="section-2"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORYX<span class="Sup">Â®</span> and other antibacterial drugs, DORYX should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_46CFE4AF-9F40-4C5A-884D-1C39F6493E15"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">DORYX Capsules contain specially coated pellets of doxycycline hyclate, a broad-spectrum antibiotic synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration.</p>
<p>The structural formula for doxycycline hyclate is</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1292FA83-E2A1-4FDA-B0DD-CCF763265FE1&amp;name=doryx-01.jpg"></div>
<p>with a molecular formula of C<span class="Sub">22</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">8</span>, HCl, Â½ C<span class="Sub">2</span>H<span class="Sub">6</span>O, Â½ H<span class="Sub">2</span>O and a molecular weight of 512.9. The chemical designation for doxycycline hyclate is [4S (4aR, 5S, 5aR, 6R, 12aS)]-4-(dimethylamino)-1,4,4a, 5,5a, 6, 11,12a-octahydro-3, 5,10,12,12a-pentahydroxy-6-methyl-1, 11-deoxonapthtacene-2-carboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. </p>
<p>Doxycycline hyclate is a yellow crystalline powder soluble in water and in solutions of alkali hydroxides and carbonates.  Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. </p>
<p>Inert ingredients in the capsule formulation are: lactose; microcrystalline cellulose; povidone; starch wheat; magnesium stearate; cellulosic polymer coating. The capsule shell and/or band contains FD and C blue No.1; FD and C yellow No. 6; D and C yellow No.10; gelatin, silicon dioxide; sodium lauryl sulfate; titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_40E53227-4FA6-4E86-B70F-E19830C6CF37"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations and in a biologically active form.  Doxycycline is virtually completely absorbed after oral administration. </p>
<p>Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2.6 mcg/mL of doxycycline at 2 hours decreasing to 1.45 mcg/mL at 24 hours. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> as low as 1-5%/72 hours in individuals with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18-22 hours) in individuals with normal and severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. </p>
<p>Hemodialysis does not alter serum half-life.</p>
<p>Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E6F1C25E-2D2D-43BD-B5E5-DF27EF1BBA47"></a><a name="section-4.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. The tetracyclines, including doxycycline, have a similar antimicrobial spectrum of activity against a wide range of gram-positive and gram-negative organisms. Cross-resistance of these organisms to tetracycline is common.</p>
<p><span class="Bold"><span class="Emphasis">Gram-Negative Bacteria</span></span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span><br><span class="Italics">Calymmatobacterium granulomatis</span><br>Haemophilus ducreyi<br><span class="Italics">Haemophilus influenzae</span><br><span class="Italics">Yersinia pestis (</span>formerly<span class="Italics"> Pasturella pestis)<br></span><span class="Italics">Francisella tularensis (</span>formerly<span class="Italics"> Pasteurella tularensis)</span><br><span class="Italics">Vibrio cholerae (</span>formerly<span class="Italics"> Vibrio comma)<br></span><span class="Italics">Bartonella bacilliformis<br></span><span class="Italics">Brucella </span>speciesÂ </p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of gram-negative microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended:</p>
<p><span class="Italics">Escherichia coli</span><br><span class="Italics">Klebsiella </span>species<br><span class="Italics">Enterobacter aerogenes</span><br><span class="Italics">Shigella </span>species<br><span class="Italics">Acinetobacter </span>species <span class="Italics">(</span>formerly<span class="Italics"> Mima </span>species <span class="Italics">and Herellea </span>species<span class="Italics">)</span><br><span class="Italics">Bacteroides </span>species </p>
<p><span class="Bold"><span class="Emphasis">Gram-Positive Bacteria</span></span></p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of gram-positive microorganisms have been shown to be resistant to tetracycline, culture and susceptibility testing are recommended. Up to 44 percent of <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pyogenes </span>and 74 percent of <span class="Italics">Streptococcus faecalis </span>have been found to be resistant to tetracycline drugs. Therefore, tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible.</p>
<p><span class="Italics">Streptococcus pyogenes</span><br><span class="Italics">Streptococcus pneumoniae</span><br>Enterococcus group <span class="Italics">(Streptococcus faecalis </span>and <span class="Italics">Streptococcus faecium)</span><br>Alpha-hemolytic streptococci (viridans group)</p>
<p><span class="Bold"><span class="Emphasis">Other Microorganisms</span></span></p>
<p>Rickettsiae<br><span class="Italics">Chlamydia psittaci</span><br><span class="Italics">Chlamydia trachomatis</span><br><span class="Italics">Mycoplasma pneumoniae</span><br><span class="Italics">Ureaplasma urealyticum</span><br><span class="Italics">Borrelia recurrentis</span><br><span class="Italics">Treponema pallidum</span><br><span class="Italics">Treponema pertenue</span><br><span class="Italics">Clostridium </span>species<br><span class="Italics">Fusobacterium fusiforme</span><br><span class="Italics">Actinomyces </span>species<br><span class="Italics">Bacillus anthracis</span><br><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span><br><span class="Italics">Entamoeba </span>species<br><span class="Italics">Balantidium coli</span><br><span class="Italics">Plasmodium falciparum</span></p>
<p>Doxycycline has been found to be active against the asexual erythrocytic forms of <span class="Italics">Plasmodium falciparum </span>but not against the gametocytes of <span class="Italics">P. falciparum. </span>The precise mechanism of action of the drug is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_2173AF7B-BFB9-4DF6-BBCE-35601FBDD738"></a><a name="section-4.2"></a><p></p>
<h2>Susceptibility Tests</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Diffusion Techniques: </span></span>Quantitative methods that require measurement of zone diameters give the most precise estimate of the susceptibility of bacteria to antimicrobial agents.  One such standard procedure<span class="Sup">1</span> that has been recommended for use with disks to test susceptibility of organisms to doxycycline uses the 30 mcg tetracycline-class disk or the 30 mcg doxycycline disk. Interpretation involves the correlation of the diameter obtained in the disk test with the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) for tetracycline or doxycycline, respectively.</p>
<p>Reports from the laboratory giving results of the standard single-disk susceptibility test with a 30 mcg tetracycline-class disk or the 30 mcg doxycycline disk should be interpreted according to the following criteria:</p>
<a name="ID_3FD84379-E815-40C5-9C43-D807B1F9D2A9"></a><table border="none" frame="void" width="434">
<col width="30.415%">
<col width="35.484%">
<col width="34.101%">
<tbody class="Headless">
<tr class="First">
<td align="center" colspan="2" valign="top"><span class="Bold"><span class="Emphasis">Zone  Diameter (mm)</span></span></td>
<td align="justify" valign="top"><span class="Bold"><span class="Emphasis">Interpretation</span></span></td>
</tr>
<tr>
<td align="center" valign="top">tetracycline</td>
<td align="center" valign="top">doxycycline</td>
<td align="justify" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">â‰¥19</td>
<td align="center" valign="top">â‰¥16</td>
<td align="justify" valign="top">Susceptible</td>
</tr>
<tr>
<td align="center" valign="top">15-18</td>
<td align="center" valign="top">13-15</td>
<td align="justify" valign="top">Intermediate</td>
</tr>
<tr class="Last">
<td align="center" valign="top">â‰¤14</td>
<td align="center" valign="top">â‰¤12</td>
<td align="justify" valign="top">Resistant</td>
</tr>
</tbody>
</table>
<p>Â </p>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited by generally achievable blood levels. A report of â€œIntermediateâ€? suggests that the organism would be susceptible if high dosage is used or if the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confined to tissues and fluids in which high antimicrobial levels are attained. A report of â€œResistantâ€? indicates that achievable concentrations are unlikely to be inhibitory, and other therapy should be selected.  </p>
<p>Standardized procedures require the use of laboratory control organisms. The 30 mcg tetracycline-class disk or the 30 mcg doxycycline disk should give the following zone diameters: </p>
<a name="ID_3808C0CF-923C-45C7-B7DF-0D40AC77A2AC"></a><table border="none" frame="void" width="434.004">
<col width="48.156%">
<col width="25.346%">
<col width="26.498%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Bold"><span class="Emphasis">Organism</span></span></td>
<td align="center" colspan="2" valign="top"><span class="Bold"><span class="Emphasis">Zone Diameter (mm)</span></span></td>
</tr>
<tr>
<td align="justify" valign="top"></td>
<td align="center" valign="top">tetracycline</td>
<td align="center" valign="top">doxycycline</td>
</tr>
<tr>
<td align="justify" valign="top">
<span class="Italics">E. coli </span>ATCC 25922</td>
<td align="center" valign="top">18-25</td>
<td align="center" valign="top">18-24</td>
</tr>
<tr class="Last">
<td align="justify" valign="top">
<span class="Italics">S. aureus </span>ATCC 25923</td>
<td align="center" valign="top">19-28</td>
<td align="center" valign="top">23-29</td>
</tr>
</tbody>
</table>
<p>Â </p>
<p><span class="Bold"><span class="Emphasis">Dilution Techniques: </span></span>Use a standardized dilution method<span class="Sup">2</span> (broth, agar, microdilution) or equivalent with tetracycline powder. The MIC values obtained should be interpreted according to the following criteria: </p>
<a name="ID_79F74CF8-CB87-4555-A29A-5CFCB18A0728"></a><table border="none" frame="void" width="423">
<col width="45.390%">
<col width="54.610%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Bold"><span class="Emphasis">MIC (mcg/mL)</span></span></td>
<td align="center" valign="top"><span class="Bold"><span class="Emphasis">Interpretation</span></span></td>
</tr>
<tr>
<td align="center" valign="top">â‰¤4</td>
<td align="center" valign="top">Susceptible</td>
</tr>
<tr>
<td align="center" valign="top">8</td>
<td align="center" valign="top">Intermediate</td>
</tr>
<tr class="Last">
<td align="center" valign="top">â‰¥16</td>
<td align="center" valign="top">Resistant</td>
</tr>
</tbody>
</table>
<p>Â </p>
<p>As with standard diffusion techniques, dilution methods require the use of laboratory control organisms. Standard tetracycline powder should provide the following MIC values:</p>
<a name="ID_92A0E769-AFB8-4E9C-86FF-CF8D436EA3F3"></a><table border="none" frame="void" width="423">
<col width="45.390%">
<col width="54.610%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Organism</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">MIC (mcg/mL)</span></span></td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">E. coli </span>ATCC 25922</td>
<td align="left" valign="top">1.0-4.0</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">S. aureus</span> ATCC 29213</td>
<td align="left" valign="top">0.25-1.0</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">E. faecalis </span>ATCC 29212</td>
<td align="left" valign="top">8-32</td>
</tr>
<tr class="Last">
<td align="left" valign="top">
<span class="Italics">P. aeruginosa </span>ATCC 27853</td>
<td align="left" valign="top">8-32</td>
</tr>
</tbody>
</table>
<p>Â </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_4FF776A5-C52D-417C-A21A-A790A0130A4F"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORYX and other antibacterial drugs, DORYX should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_24A0C714-4FAA-44F5-8E33-3C816D531636"></a><a name="section-5.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Doxycycline is indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<dl>
<dt>Â </dt>
<dd>Rocky Mountain spotted <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, typhus <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and the typhus group, Q <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>,<br>rickettsialpox, and tick <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> caused by Rickettsiae. </dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Mycoplasma pneumoniae. </span>
</dd>
<dt>Â </dt>
<dd>Lymphogranuloma venereum caused by <span class="Italics">Chlamydia trachomatis</span>.</dd>
<dt>Â </dt>
<dd>Psittacosis (ornithosis) caused by <span class="Italics">Chlamydia psittaci.</span>
</dd>
<dt>Â </dt>
<dd>Trachoma caused by <span class="Italics">Chlamydia trachomatis</span>, although the infectious agent is not always eliminated as judged by immunofluorescence.</dd>
<dt>Â </dt>
<dd>Inclusion <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by <span class="Italics">Chlamydia trachomatis</span>.</dd>
<dt>Â </dt>
<dd>Uncomplicated urethral, endocervical or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults caused by <span class="Italics">Chlamydia trachomatis</span>.</dd>
<dt>Â </dt>
<dd>Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by <span class="Italics">Ureaplasma urealyticum</span>.</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="440637" conceptname="Relapsing fever">Relapsing fever</span> due to <span class="Italics">Borrelia recurrentis</span>.</dd>
</dl>
<p>Doxycycline also is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-negative microorganisms:</p>
<dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">Chancroid</span> caused by <span class="Italics">Haemophilus ducreyi.</span>
</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> due to <span class="Italics">Yersinia pestis </span>(formerly <span class="Italics">Pasteurella pesti</span>s).</dd>
<dt>Â </dt>
<dd>Tularemia due to <span class="Italics">Francisella tularensis </span>(formerly <span class="Italics">Pasteurella tularensi</span>s).</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">Cholera</span> caused by <span class="Italics">Vibrio cholerae </span>(formerly <span class="Italics">Vibrio comma</span>).</dd>
<dt>Â </dt>
<dd>Campylobacter fetus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Campylobacter fetus </span>(formerly <span class="Italics">Vibrio fetu</span>s).</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">Brucellosis</span> due to <span class="Italics">Brucella </span>species (in conjunction with streptomycin).</dd>
<dt>Â </dt>
<dd>Bartonellosis due to <span class="Italics">Bartonella bacilliformis</span>.</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">Granuloma inguinale</span> caused by <span class="Italics">Calymmatobacterium granulomatis.</span>
</dd>
</dl>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. </p>
<p>Doxycycline is indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:</p>
<dl>
<dt>Â </dt>
<dd><span class="Italics">Escherichia coli.</span></dd>
<dt>Â </dt>
<dd>
<span class="Italics">Enterobacter aerogenes</span> (formerly <span class="Italics">Aerobacter aerogenes</span>).</dd>
<dt>Â </dt>
<dd>
<span class="Italics">Shigella</span> species.</dd>
<dt>Â </dt>
<dd>
<span class="Italics">Acinetobacter</span> species (formerly <span class="Italics">Mima</span> species and <span class="Italics">Herellea</span> species).</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Haemophilus influenzae</span>. </dd>
<dt>Â </dt>
<dd>Respiratory tract and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> caused by <span class="Italics">Klebsiella</span> species. </dd>
</dl>
<p>Doxycycline is indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-positive microorganisms when bacteriological testing indicates appropriate susceptibility to the drug:</p>
<dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infections</span> caused by <span class="Italics">Streptococcus pneumoniae </span>(formerly <span class="Italics">Diplococcus Pneumoniae)</span>
</dd>
</dl>
<p><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> due to <span class="Italics">Bacillus anthracis</span>, including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized <span class="Italics">Bacillus anthracis</span>. </p>
<p>When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<dl>
<dt>Â </dt>
<dd>Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> caused by <span class="Italics">Neisseria gonorrhoeae.</span>
</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> caused by <span class="Italics">Treponema pallidum. </span>
</dd>
<dt>Â </dt>
<dd>Yaws caused by <span class="Italics">Treponema pertenue</span>.</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> due to <span class="Italics">Listeria monocytogenes</span>.</dd>
<dt>Â </dt>
<dd>Vincentâ€™s <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Fusobacterium fusiforme</span>.</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span> caused by<span class="Italics"> Actinomyces israelii</span>.</dd>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by <span class="Italics">Clostridium </span>species.</dd>
</dl>
<p>In acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>, doxycycline may be a useful adjunct to amebicides.</p>
<p>In severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, doxycycline may be useful adjunctive therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_062159F6-69EF-4B3B-A01F-43B55140D030"></a><a name="section-5.2"></a><p></p>
<h2>Prophylaxis:</h2>
<p class="First">Doxycycline is indicated for the prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> due to <span class="Italics">Plasmodium falciparum </span>in short-term travelers (&lt;4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. See <a href="#i4i_dosage_admin_ID_8305283C-6A21-467D-8318-7A3BF80A2868">DOSAGE AND ADMINISTRATION</a> section and Information for Patients subsections of the <a href="#i4i_precautions_ID_8155D820-65E1-422C-9464-42F76F70EC21">PRECAUTIONS</a> section.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_AE2E9FC8-5D90-4674-8975-47A2010E8194"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">The drug is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the tetracyclines.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_017732A4-B719-4875-B22C-DB0E053573D1"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but it has been observed following repeated short-term courses. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP, EXCEPT FOR <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">ANTHRAX</span>, INCLUDING INHALATIONAL <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">ANTHRAX</span> (POST-EXPOSURE), UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including DORYX<span class="Sup">Â®</span> Capsules, 75 mg and 100 mg, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile.</span></p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p>All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.</p>
<p>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of potential hazard to the fetus.</p>
<p>The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_8155D820-65E1-422C-9464-42F76F70EC21"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_39343830-6499-4015-9DD1-D7488215AABB"></a><a name="section-8.1"></a><p></p>
<h2>General:</h2>
<p class="First">As with other antibiotic preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, the antibiotic should be discontinued and appropriate therapy instituted.</p>
<p>Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> in adults have been reported in individuals receiving tetracyclines. These conditions disappeared when the drug was discontinued.</p>
<p>Incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy, when indicated.</p>
<p>Doxycycline offers substantial but not complete suppression of the asexual blood stages of <span class="Italics">Plasmodium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<p>Doxycycline does not suppress <span class="Italics">P. falciparumâ€™s </span>sexual blood stage gametocytes. Subjects completing this <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> regimen may still transmit the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to mosquitoes outside endemic areas. </p>
<p>Prescribing DORYX in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_01683464-7E62-49A8-A873-A9A17118D896"></a><a name="section-8.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Patients taking doxycycline for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis should be advised:</p>
<ul>
<li>that no present-day antimalarial agent, including doxycycline, guarantees protection against <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</li>
<li>to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from dusk to dawn (e.g., staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellant).</li>
<li>that doxycycline prophylaxis:<ul>
<li>should begin 1-2 days before travel to the malarious area, Â </li>
<li>should be continued daily while in the malarious area and after leaving the malarious area,</li>
<li>should be continued for 4 further weeks to avoid development of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> after returning from an endemic area,</li>
<li>should not exceed 4 months.</li>
</ul>
</li>
</ul>
<p>All patients taking doxycycline should be advised:</p>
<ul>
<li>to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, etc.) occurs. Sunscreen or sunblock should be considered (See <a href="#i4i_warnings_ID_017732A4-B719-4875-B22C-DB0E053573D1">WARNINGS</a>).</li>
<li>to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration (See <a href="#i4i_adverse_effects_ID_20DE02E3-FE32-4DA3-BEEE-A26C6F261AC0">ADVERSE REACTIONS</a>).</li>
<li>that the absorption of tetracyclines is reduced when taken with foods, especially those that contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. (See <a href="#i4i_drug_interaction_ID_321B5A95-F3C3-4D33-9938-EF5E0409EE38">Drug interactions</a>).</li>
<li>that the absorption of tetracyclines is reduced when taking bismuth subsalicylate (See <a href="#i4i_drug_interaction_ID_321B5A95-F3C3-4D33-9938-EF5E0409EE38">Drug interactions</a>).</li>
<li>that the use of doxycycline might increase the incidence of <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>.</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
<p>Patients should be counseled that antibacterial drugs including DORYX should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When DORYX is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by DORYX or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_ID_5B22177F-FCFE-4ACA-BDBE-14703F513367"></a><a name="section-8.3"></a><p></p>
<h2>Laboratory tests</h2>
<p class="First">In venereal disease when coexistent <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> is suspected, dark-field examination should be done before treatment is started and the blood serology repeated monthly for at least 4 months.</p>
<p>In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic studies should be performed.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_321B5A95-F3C3-4D33-9938-EF5E0409EE38"></a><a name="section-8.4"></a><p></p>
<h2>Drug interactions</h2>
<p class="First">Because tetracyclines have been shown to depress plasma <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. </p>
<p>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.</p>
<p>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations. </p>
<p>Absorption of tetracyclines is impaired by bismuth subsalicylate.</p>
<p>Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.</p>
<p>The concurrent use of tetracycline and Penthrane<span class="Sup">Â®</span> (methoxyflurane) has been reported to result in fatal renal toxicity.</p>
<p>Concurrent use of tetracycline may render oral contraceptives less effective.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_ID_1E9A06C4-0F90-49C4-BF34-9BFBE49659FB"></a><a name="section-8.5"></a><p></p>
<h2>Drug/Laboratory Test Interaction</h2>
<p class="First">False elevations of urinary catecholamines may occur due to interference with the fluorescence test.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_61955032-9D32-43DB-AE10-5B93CC0A33A3"></a><a name="section-8.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with the related antibiotics, oxytetracycline (adrenal and pituitary tumors) and minocycline (<span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumors</span>). </p>
<p>Likewise, although mutagenicity studies of doxycycline have not been  conducted, positive results in <span class="Italics">in vitro</span> mammalian cell assays have been reported for related antibiotics (tetracycline, oxytetracycline).</p>
<p>Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_42BE5A2D-D079-49E0-9DBD-641DC0CA816C"></a><a name="section-8.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_ID_284E5F2F-F5BD-4831-BCFA-D45873AAE104"></a><a name="section-8.7.1"></a><p></p>
<h3>Teratogenic Effects. Pregnancy Category D:</h3>
<p class="First">There are no adequate and well-controlled studies on the use of doxycycline in pregnant women. The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for the treatment of <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk<span class="Sup">3</span>.</p>
<p>A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. Sixty-three (0.19%) of the controls and 56 (0.30%) of the cases were treated with doxycycline. This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation) with the exception of a marginal relationship with <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defect</span> based on only two exposed cases<span class="Sup">4</span>.</p>
<p>A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age<span class="Sup">5</span>.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_ID_0369265B-4773-459E-91FB-5F9851111969"></a><a name="section-8.7.2"></a><p></p>
<h3>Nonteratogenic effects: </h3>
<p class="First">(See <a href="#i4i_warnings_ID_017732A4-B719-4875-B22C-DB0E053573D1">WARNINGS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_ID_A8AE37A7-2426-47F1-8B70-5B48C92A64F0"></a><a name="section-8.8"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of tetracyclines on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_A1C26189-A990-4DEB-8BFD-766D4AD8D1DF"></a><a name="section-8.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated; however, the effects of prolonged exposure to doxycycline in breast milk are unknown<span class="Sup">6</span>. Because of the potential for serious adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See <a href="#i4i_warnings_ID_017732A4-B719-4875-B22C-DB0E053573D1">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_71E504EE-0F5C-419E-85BB-9AB6D057A883"></a><a name="section-8.10"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">See <a href="#i4i_warnings_ID_017732A4-B719-4875-B22C-DB0E053573D1">WARNINGS</a> and <a href="#i4i_dosage_admin_ID_8305283C-6A21-467D-8318-7A3BF80A2868">DOSAGE AND ADMINISTRATION</a>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_DCB22400-6949-4C01-98E3-825C86EC2F9E"></a><a name="section-8.11"></a><p></p>
<h2>Geriatric use</h2>
<p class="First">Clinical studies with DORYX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of the decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_20DE02E3-FE32-4DA3-BEEE-A26C6F261AC0"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Due to oral doxycyclineâ€™s virtually complete absorption, side effects to the lower bowel, particularly <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines: </p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported rarely.  These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcerations</span> have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline class. Most of these patients took medications immediately before going to bed (see <a href="#i4i_dosage_admin_ID_8305283C-6A21-467D-8318-7A3BF80A2868">DOSAGE AND ADMINISTRATION</a>).</p>
<p>Skin: Maculopapular and erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>. <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> has been reported but is uncommon. <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> is discussed above (see <a href="#i4i_warnings_ID_017732A4-B719-4875-B22C-DB0E053573D1">WARNINGS</a>).</p>
<p>Renal toxicity: Rise in BUN has been reported and is apparently dose-related (see <a href="#i4i_warnings_ID_017732A4-B719-4875-B22C-DB0E053573D1">WARNINGS</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4101602" conceptname="Henoch-Schonlein purpura">anaphylactoid purpura</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, and exacerbation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<p>Blood: <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported.</p>
<p>Other: Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> in adults (See <a href="#i4i_precautions_ID_8155D820-65E1-422C-9464-42F76F70EC21">PRECAUTIONS</a>-<a href="#i4i_precautions_general_ID_39343830-6499-4015-9DD1-D7488215AABB">General:</a>).</p>
<p>When given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_EEC7455B-ADE2-493D-845F-01669C102F71"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_8305283C-6A21-467D-8318-7A3BF80A2868"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.</p>
<p>Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day.  The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (particularly chronic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the urinary tract), 100 mg every 12 hours is recommended.</p>
<p>For children above eight years of age: The recommended dosage schedule for children weighing 100 pounds or less is 2 mg/lb of body weight divided into two doses on the first day of treatment, followed by 1 mg/lb of body weight given as a single daily dose or divided into two doses on subsequent days. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> up to 2 mg/lb of body weight may be used. For children over 100 lb, the usual adult dose should be used.</p>
<p>The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage.</p>
<p>When used in <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, therapy should be continued for 10 days.</p>
<p>Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration (see <a href="#i4i_adverse_effects_ID_20DE02E3-FE32-4DA3-BEEE-A26C6F261AC0">ADVERSE REACTIONS</a>).</p>
<p>If <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span> occurs, doxycycline may be given with food or milk.</p>
<p>Studies to date have indicated that administration of doxycycline at the usual recommended doses does not lead to excessive accumulation of the antibiotic in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Uncomplicated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults (except anorectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in men): 100 mg, by mouth, twice a day for 7 days.Â As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose. The dose may be administered with food, including milk or carbonated beverage, as required. </p>
<p>Uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults caused by <span class="Italics">Chlamydia trachomatis: </span>100 mg by mouth, twice a day for 7 days.</p>
<p>Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> (NGU) caused by <span class="Italics">C. trachomatis </span>and <span class="Italics">U. urealyticum: </span>100 mg, by mouth, twice a day for 7 days.</p>
<p><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> â€“ early: Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice a day for 2 weeks.</p>
<p><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> of more than one yearâ€™s duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice a day for 4 weeks.</p>
<p>Acute epididymo-<span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span> caused by <span class="Italics">N. gonorrhoeae: </span>100 mg, by mouth, twice a day for at least 10 days.</p>
<p>Acute epididymo-<span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span> caused by <span class="Italics">C. trachomatis: </span>100 mg, by mouth, twice a day for at least 10 days.</p>
<p>For prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>: For adults, the recommended dose is 100 mg daily. For children over 8 years of age, the recommended dose is 2 mg/kg given once daily up to the adult dose. Prophylaxis should begin 1-2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.</p>
<p>Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure): </p>
<p>ADULTS: 100 mg, of doxycycline, by mouth, twice a day for 60 days.</p>
<p>CHILDREN: weighing less than 100 lb (45 kg); 1 mg/lb (2.2 mg/kg) of body weight, by mouth, twice a day for 60 days. Children weighing 100 lb or more should receive the adult dose.</p>
<p><span class="Bold"><span class="Emphasis">Sprinkling the Capsule Contents on Applesauce</span></span></p>
<p>DORYX Capsules may also be administered by carefully opening the capsules and sprinkling the capsule contents on a spoonful of applesauce. However, any loss of pellets in the transfer would prevent using the dose. The applesauce should be swallowed immediately without chewing and followed with a cool 8-ounce glass of water to ensure complete swallowing of the capsule contents. The applesauce should not be hot, and it should be soft enough to be swallowed without chewing. In the event that a prepared dose of applesauce/DORYX pellets cannot be taken immediately, the mixture should be discarded and not stored for later use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_0182E682-0EC9-4614-BE77-EFF2D32ABA2E"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">DORYX<span class="Sup">Â®</span> (doxycycline hyclate) Delayed-Release Capsules, 100 mg have a dark yellow transparent body, with light blue opaque cap; the capsule bearing the inscription â€œDORYXâ€? and â€œWCâ€? in a circle, printed in white. Pellets are colored yellow. Each capsule contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline, supplied in:</p>
<p>Bottles of 50 capsulesâ€¦N 0430-0838-19</p>
<p>DORYX<span class="Sup">Â®</span> (doxycycline hyclate) Delayed-Release Capsules, 75 mg have an orange transparent body, with green opaque cap; the capsule bearing the inscription â€œDORYXâ€? and â€œ75 mgâ€? in black. Pellets are colored yellow. Each capsule contains specially coated pellets of doxycycline hyclate equivalent to 75 mg of doxycycline, supplied in:</p>
<p>Bottles of 60 capsulesâ€¦N 0430-0836-20</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_ID_71C21950-5C80-443A-9BC4-0A51B60EB352"></a><a name="section-12.1"></a><p></p>
<h2>STORAGE CONDITIONS</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Store at controlled room temperature below 25Â°C (77Â°F).</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_ID_AAD8E458-3D0C-44B2-AA6A-EA0C4384BF8A"></a><a name="section-13"></a><p></p>
<h1>ANIMAL PHARMACOLOGY AND TOXICOLOGY</h1>
<p class="First">Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO<span class="Sub">4</span>, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO<span class="Sub">4</span>, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.</p>
<p>Minocycline, tetracycline PO<span class="Sub">4</span>, methacycline, doxycycline, tetracycline base, oxytetracycline HCl, and tetracycline HCl were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> with high radioiodine uptake in rats fed a relatively high iodine diet.</p>
<p>Treatment of various animal species with this class of drugs has also resulted in the induction of <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in the following: in rats and dogs (minocycline); in chickens (chlortetracycline); and in rats and mice (oxytetracycline). Adrenal gland <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> has been observed in goats and rats treated with oxytetracycline. </p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_ID_3ECCDC49-580C-4E6C-9098-F4F565B15A96"></a><a name="section-14"></a><p></p>
<h1>Refeences:</h1>
<ol>
<li>National Committee for Clinical Laboratory Standards, <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests</span>, Fourth Edition. Approved Standard NCCLS Document M2-A4, Vol. 10, No.7 NCCLS Villanova, PA, April 1990.</li>
<li>National Committee for Clinical Laboratory Standards, <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span>, Second Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8 NCCLS, Villanova, PA, April 1990.</li>
<li>Friedman JM and Polifka JE. <span class="Italics">Teratogenic Effects of Drug</span>s. <span class="Italics">A Resource for Clinicians </span>(TERIS).Â Baltimore, MD: The Johns Hopkins University Press: 2000: 149-195.</li>
<li>Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. <span class="Italics">Obstet Gynecol </span>1997; 89: 524-528.</li>
<li>Horne HW Jr. and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. <span class="Italics">Int J Fertil </span>1980; 25:315-317.</li>
<li>Hale T. <span class="Italics">Medications and Mothers Milk</span>. 9th.edition. Amarillo, TX: Pharmasoft Publishing 2000; 225-226.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_355C4CEE-2C5B-4DEA-AAA5-74CF41431C43"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold"><span class="Emphasis">Rx only</span></span></p>
<p>Manufactured by:</p>
<p>Mayne Pharma International Pty Ltd</p>
<p>1538 Main North Road</p>
<p>Salisbury South, South Australia 5106</p>
<p>Marketed by:</p>
<p>Warner Chilcott (US), Inc.</p>
<p>Rockaway, NJ 07866</p>
<p>Revised March 2007                                                                             0838G0110</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DORYXÂ 		
					</strong><br><span class="contentTableReg">doxycycline hyclate capsule, delayed release pellets</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0836</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>doxycycline hyclate</strong> (doxycycline) </td>
<td class="formItem"></td>
<td class="formItem">75Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSIC POLYMER COATING</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D &amp; C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD &amp; C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD &amp; C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MICROCRYSTALINE CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH WHEAT</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE,Â GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DORYX;75mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0836-95</td>
<td class="formItem">24  in 1 KIT</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0430-0836-20</td>
<td class="formItem">48  in 1 KIT</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DORYXÂ 		
					</strong><br><span class="contentTableReg">doxycycline hyclate capsule, delayed release pellets</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0838</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>doxycycline hyclate</strong> (doxycycline) </td>
<td class="formItem"></td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSIC POLYMER COATING</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D &amp; C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD &amp; C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD &amp; C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MICROCRYSTALINE CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH WHEAT</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW,Â BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DORYX;WC</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">true</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0838-19</td>
<td class="formItem">48  in 1 KIT</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0430-0838-95</td>
<td class="formItem">24  in 1 KIT</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Warner Chilcott (US), Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>85944CB9-B1E6-D741-1D5C-72C471740A06</div>
<div>Set id: 1292FA83-E2A1-4FDA-B0DD-CCF763265FE1</div>
<div>Version: 2</div>
<div>Effective Time: 20070409</div>
</div>
</div>Â <div class="DistributorName">Warner Chilcott (US), Inc.</div></p>
</body></html>
